• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals (NQ: IONS )

    46.65 -1.31 (-2.73%)
    Streaming Delayed Price Updated: 3:25 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ionis Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
    Via Benzinga
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Masters In Trading - Saturday, June 22
    In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
    Via Talk Markets
    Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
    Via Benzinga
    Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
    Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year. 
    Via Benzinga
    Exposures Product Safety
    The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
    Via Benzinga
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
    Via Benzinga
    Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
    The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. 
    Via Benzinga
    Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
    Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. 
    Via Benzinga
    Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
    From Biogen Inc.
    Via GlobeNewswire
    The 3 Most Undervalued Pharma Stocks to Buy in May 2024
    Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
    Via InvestorPlace
    Earnings Scheduled For February 21, 2024
    Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
    Via Benzinga
    Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
    Via Benzinga
    IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
    IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
    Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with... 
    Via Benzinga
    Are These 5 Undervalued Stocks Ready to Break Out?
    Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
    Via MarketBeat
    New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
    From Biogen Inc.
    Via GlobeNewswire
    JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
    Via Benzinga
    Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
    Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval. 
    Via Benzinga
    Exposures Product Safety
    Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
    Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission. 
    Via Benzinga
    Exposures Product Safety
    Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
    Via Investor's Business Daily
    2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
    A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... 
    Via Benzinga
    Topics ETFs
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies
    These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024. 
    Via InvestorPlace
    Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
    Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am 
    Via Benzinga
    Exposures Product Safety
    New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
    Friday, FDA approved AstraZeneca 
    Via Benzinga
    Exposures Product Safety
    Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
    Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.